Biogen shares are trading higher after the company and Eisai presented data showing three years of continuous treatment with dual-acting LEQEMBI continued to benefit early Alzheimer's patients.
Portfolio Pulse from Benzinga Newsdesk
Biogen shares are trading higher after the company and Eisai presented data showing three years of continuous treatment with dual-acting LEQEMBI continued to benefit early Alzheimer's patients.
July 30, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen shares are trading higher after the company and Eisai presented data showing three years of continuous treatment with dual-acting LEQEMBI continued to benefit early Alzheimer's patients.
The positive data from the LEQEMBI treatment study is likely to boost investor confidence in Biogen's product pipeline, leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100